GSK said it will use its established manufacturing network in Belgium to support production. The companies will also work together to research, develop and manufacture several mRNA vaccine ...

The High Court ruled on a significant patent dispute involving Pfizer and GSK, addressing costs and confidentiality.

GSK has made another investment in its manufacturing ... unveiled plans to build a $270 million-plus vaccines facility in Belgium.

As one of the leading vaccine developers, GSK is keen to facilitate the exchange of intellectual know-how between the 2,000 scientists at its R&D sites in Rixensart (Belgium), Rockville (Maryland ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio. The purchase ...

Working out of three global R&D centres in Belgium, Italy and the US, GSK’s 2,500 vaccine scientists have built a pipeline of 16 candidate vaccines across all R&D phases. Over the past five ...